Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

Journal of the National Cancer Institute

Volumn 109, Issue 7, 2017, Pages

  Tota, Joseph E ^a   Struyf, Frank ^b   Merikukka, Marko ^c   Gonzalez, Paula ^d   Kreimer, Aimée R ^a   Bi, Dan ^b   Castellsagué, Xavier ^e   De Carvalho, Newton S ^f   Garland, Suzanne M ^g,h,i   Harper, Diane M ^j   Karkada, Naveen ^k   Peters, Klaus ^l   Pope, Willy A J ^m   Porras, Carolina ^d   Quint, Wim ⁿ   Rodriguez, Ana Cecilia ^d   Schiffman, Mark ^a   Schussler, John ^o   Rachel Skinner, S ^p,q   Teixeira, Júlio Cesar ^r   Hildesheim, Allan ^a   Lehtinen, Matti ^s   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b GSK   (Belgium)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^g ROYAL WOMEN'S HOSPITAL   (Australia)

^h MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j DARTMOUTH MEDICAL SCHOOL   (United States)

^k GlaxoSmithKline Pharmaceuticals Ltd   (India)

^l DDL Diagnostic Laboratory ^*  (Germany)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ DDL DIAGNOSTIC LABORATORY   (Netherlands)

^o INFORMATION MANAGEMENT SERVICES INC   (United States)

^p UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^q UNIVERSITY OF SYDNEY   (Australia)

^r UNIVERSITY OF CAMPINAS   (Brazil)

^s UNIVERSITY OF TAMPERE   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 40; HUMAN PAPILLOMAVIRUS TYPE 42; HUMAN PAPILLOMAVIRUS TYPE 43; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 54; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN PAPILLOMAVIRUS TYPE 74; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; VACCINATION; VIRAL CLEARANCE; WART VIRUS; ADOLESCENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIAL; COSTA RICA; IMMUNOLOGY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COSTA RICA; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 85016184565     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw300     Document Type: Article

References (33)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1): 12-19.
3. Tota JE, Chevarie-Davis M, Richardson LA, et al. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Prev Med. 2011;53(suppl 1):S12-S21.
4. Lehtinen M, Paavonen J. Vaccination against human papillomaviruses shows great promise. Lancet. 2004;364(9447):1731-1732.
5. Tota JE, Ramanakumar AV, Jiang M, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol. 2013;178(4):625-634.
6. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: Addressing the limits of epidemiology at the borderline. Infect Agent Cancer. 2009;4:8.
7. IARC. Human Papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: IARC; 2011.
8. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4): 927-935.
9. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278-85.
10. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056.
11. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012; 7(1):38.
12. HarperDM, Franco EL,Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-1255.
13. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943.
14. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926-935.
15. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199(7):936-944.
16. Herrero R, Wacholder S, Rodriguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1(5): 408-419.
17. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1): 100-110.
18. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8): 711-723.
19. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962-1973.
20. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008;26(37):4795-4808.
21. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369(9580):2161-2170.
22. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998;153(6):1731-1739.
23. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999;37(8):2508-2517.
24. van Doorn LJ, Molijn A, Kleter B, et al. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broadspectrum and type-specific PCR. J Clin Microbiol. 2006;44(9):3292-3298.
25. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008;4(6):425-434.
26. Szarewski A, Skinner SR, Garland SM, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): An unexpected observation. J Infect Dis. 2013;208(9):1391-1396.
27. Lehtinen M, Apter D, Baussano I, et al. Characteristics of a clusterrandomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine. 2015;33(10):1284-1290.
28. Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-80.
29. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130(2): e249-e256.
30. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013;32(1):26-32.
31. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A. 1997;94(12):6571-6576.
32. Tota JE, Ramanakumar AV, Villa LL, et al. Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: Masking of HPV52 by HPV16 in anogenital specimens. Cancer Epidemiol Biomarkers Prev. 2015;24(1):286-290.
33. Palmroth J, Merikukka M, Paavonen J, et al. Occurrence of vaccine and nonvaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Cancer. 2012;131(12):2832-2838.